TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21878847

Group type: EXPERIMENTAL
Intervention: Topical dorzolamide 2%-timolol 0.5% twice a day
Number of subjects: 17

Group type: COMPARATOR
Intervention: No additional drops (control group)
Number of subjects: 17
Study: 19911481

Group type: EXPERIMENTAL
Intervention: Peer support
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: Pager messaging
Number of subjects: 224

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 224
Study: 17343821

Group type: EXPERIMENTAL
Intervention: Pre-treatment SSRI use
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Post-treatment SSRI use
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Pre-treatment A/D use
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Post-treatment A/D use
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Pre-treatment BZ use
Number of subjects: 105
Study: 15295743

Group type: COMPARATOR
Intervention: Home-based resistance exercise program, 3 days per week for 12 weeks
Number of subjects: 20
Study: 11211069

Group type: EXPERIMENTAL
Intervention: Fear slides
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Disgust slides
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Erotic slides
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nurturant slides
Number of subjects: 0

Group type: COMPARATOR
Intervention: Neutral slides
Number of subjects: 0
Study: 9334143

Group type: EXPERIMENTAL
Intervention: Pefloxacin mesylate, administered twice a day in a daily dose of 0.8 to 1.2 g
Number of subjects: 0
Study: 8440104

Group type: EXPERIMENTAL
Intervention: Nasal continuous positive airway pressure at 10 cm H2O
Number of subjects: 10

Group type: COMPARATOR
Intervention: Mask continuous positive airway pressure at 10 cm H2O
Number of subjects: 10
Study: 3440039

Group type: EXPERIMENTAL
Intervention: Nifedipine (Pidilat)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Commercially available reference preparation
Number of subjects: 12
Study: 31524967

Group type: EXPERIMENTAL
Intervention: Microneedling followed by topical application of 5-fluorouracil
Number of subjects: 27

Group type: COMPARATOR
Intervention: Microneedling alone
Number of subjects: 27
Study: 29638190

Group type: EXPERIMENTAL
Intervention: 11+ injury prevention programme
Number of subjects: 82

Group type: COMPARATOR
Intervention: Standard warm-up (Control)
Number of subjects: 82
Study: 26786148

Group type: EXPERIMENTAL
Intervention: P1000/Ca0 (1 g/d phosphorus)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: P1000/Ca500 (1 g/d phosphorus and 0.5 g/d calcium)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: P1000/Ca1000 (1 g/d phosphorus and 1 g/d calcium)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo (sherbet powder)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: All interventions
Number of subjects: 62
Study: 24645901

Group type: EXPERIMENTAL
Intervention: Korean Parent Training Program (KPTP)
Number of subjects: 48
Study: 23768674

Group type: EXPERIMENTAL
Intervention: Positive training
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Negative training
Number of subjects: 135

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 135
Study: 20610444

Group type: EXPERIMENTAL
Intervention: Abatacept
Number of subjects: 1043
Study: 18825581

Group type: EXPERIMENTAL
Intervention: Social support group attendance
Number of subjects: 440
Study: 17373141

Group type: EXPERIMENTAL
Intervention: Lidocaine patch
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Opioid analgesics
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nortriptyline
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Amitriptyline
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gabapentin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Antiviral and analgesic therapies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Childhood vaccine against varicella zoster virus
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: More potent vaccine against varicella for adults
Number of subjects: 0
Study: 14649578

Group type: EXPERIMENTAL
Intervention: Fibrin sealant (FS) 10 mL total
Number of subjects: 81

Group type: COMPARATOR
Intervention: Standard of care alone
Number of subjects: 81
Study: 11001889

Group type: EXPERIMENTAL
Intervention: Prophylactic methylprednisolone (0.5 mg/kg on days 14 to 20, 1 mg/kg on days 21 to 34, 0.5 mg/kg on days 35 to 48, tapered and discontinued on day 110)
Number of subjects: 108

Group type: COMPARATOR
Intervention: No prophylactic methylprednisolone
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Prophylactic methylprednisolone
Number of subjects: 108
Study: 9006240

Group type: EXPERIMENTAL
Intervention: diet and exercise program
Number of subjects: 118
Study: 7970340

Group type: EXPERIMENTAL
Intervention: Patients with visible abdominal bloating
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Patients with visible abdominal bloating during episodes of bloating
Number of subjects: 46

Group type: COMPARATOR
Intervention: Normal volunteers (control group)
Number of subjects: 46
Study: 3307283

Group type: EXPERIMENTAL
Intervention: Immobilization for 3 weeks
Number of subjects: 112

Group type: COMPARATOR
Intervention: Analgetic treatment without immobilization
Number of subjects: 112
Study: 28987524

Group type: EXPERIMENTAL
Intervention: Multifaceted hand hygiene program (increased availability of alcohol-based handrub, HH promotion, staff education, local work groups)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 26
Study: 26156412

Group type: EXPERIMENTAL
Intervention: CoQ10 supplementation (100 mg once a day for 12 weeks)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study: 25145970

Group type: EXPERIMENTAL
Intervention: Text messages containing antenatal health information delivered in English, Xhosa, or Afrikaans according to participant preference
Number of subjects: 206

Group type: COMPARATOR
Intervention: Control group receiving no text messages
Number of subjects: 206
Study: 21779958

Group type: EXPERIMENTAL
Intervention: Idebenone at a weight-adjusted dose of 1,350/2,250 mg/day for 12 months
Number of subjects: 68

Group type: COMPARATOR
Intervention: Idebenone at a weight-adjusted dose of 450/900 or 1,350/2,250 mg/day for 6 months (during the IONIA study)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Placebo for 6 months (during the IONIA study)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Idebenone at a weight-adjusted dose of 1,350/2,250 mg/day for 12 months (IONIA-E study)
Number of subjects: 68
Study: 19176289

Group type: EXPERIMENTAL
Intervention: Interferon‐beta (IFNbeta) treatment
Number of subjects: 219

Group type: COMPARATOR
Intervention: Healthy controls (HC)
Number of subjects: 219

Group type: COMPARATOR
Intervention: Untreated MS patients
Number of subjects: 219
Study: 17445100

Group type: EXPERIMENTAL
Intervention: Eletriptan 40 mg
Number of subjects: 267

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 267
Study: 15621990

Group type: EXPERIMENTAL
Intervention: Training program for sentinel lymph node biopsy
Number of subjects: 226
Study: 12475391

Group type: EXPERIMENTAL
Intervention: BATT 10 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: BATT 20 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: BATT 30 mg
Number of subjects: 24
Study: 9552036

Group type: EXPERIMENTAL
Intervention: ECycloF (infusional fluorouracil, epirubicin, and cyclophosphamide)
Number of subjects: 96

Group type: COMPARATOR
Intervention: ECisF (infusional fluorouracil, epirubicin, and cisplatin)
Number of subjects: 96
Study: 8160616

Group type: EXPERIMENTAL
Intervention: Decaffeinated coffee
Number of subjects: 186

Group type: COMPARATOR
Intervention: Caffeinated coffee (control)
Number of subjects: 186
Study: 3341564

Group type: EXPERIMENTAL
Intervention: Topical application of EMLA cream for 15 minutes
Number of subjects: 0

Group type: COMPARATOR
Intervention: Local injection of lidocaine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Topical application of EMLA cream for 80 minutes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Topical application of EMLA cream for 100 minutes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Topical application of EMLA cream for 120 minutes
Number of subjects: 0
Study: 30005019

Group type: EXPERIMENTAL
Intervention: 100% daily dosing of TDF/FTC for 12 weeks
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: 67% daily dosing of TDF/FTC for 12 weeks
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: 33% daily dosing of TDF/FTC for 12 weeks
Number of subjects: 47
Study: 28399933

Group type: EXPERIMENTAL
Intervention: Intranasal administration of ketamine (4.0 mg/kg, maximum 100 mg) and midazolam (0.2 mg/kg, maximum 5.0 mg)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Oral administration of ketamine (4.0 mg/kg, maximum 100 mg) and midazolam (0.5 mg/kg, maximum 20 mg)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Oral administration of midazolam (1.0 mg/kg, maximum 20 mg)
Number of subjects: 84
Study: 26018529

Group type: EXPERIMENTAL
Intervention: CogState Schizophrenia Battery (SB)
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: MATRICS Consensus Cognitive Battery (MCCB)
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: MATRICS Consensus Cognitive Battery (MCCB) and CogState Schizophrenia Battery (SB)
Number of subjects: 143
Study: 23982225

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT) focusing on behavioral exposure
Number of subjects: 49
Study: 21939883

Group type: EXPERIMENTAL
Intervention: Bacteriostatic normal saline (BNS)
Number of subjects: 56

Group type: COMPARATOR
Intervention: 1% buffered lidocaine (Lido)
Number of subjects: 56
Study: 18310164

Group type: EXPERIMENTAL
Intervention: Experimental intervention (breastfeeding promotion intervention)
Number of subjects: 17046
Study: 17227520

Group type: EXPERIMENTAL
Intervention: F-actin ELISA
Number of subjects: 170

Group type: COMPARATOR
Intervention: SMA-IFT
Number of subjects: 170
Study: 14624699

Group type: EXPERIMENTAL
Intervention: 12/15/18 diet group (1200 kcal/day for 12 weeks, 1500 kcal/day for 16 weeks, 1800 kcal/day for 12 weeks)
Number of subjects: 90

Group type: COMPARATOR
Intervention: 15/18 diet group (1500 kcal/day for 28 weeks, 1800 kcal/day for 12 weeks)
Number of subjects: 90
Study: 10934672

Group type: EXPERIMENTAL
Intervention: Simvastatin 40 mg
Number of subjects: 14

Group type: COMPARATOR
Intervention: Simvastatin 40 mg + Irbesartan 300 mg
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 14
Study: 8925993

Group type: EXPERIMENTAL
Intervention: Mothers with EPH gestosis
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Children from mothers with EPH gestosis
Number of subjects: 61

Group type: COMPARATOR
Intervention: Control group (healthy women and their children)
Number of subjects: 61
Study: 1477436

Group type: EXPERIMENTAL
Intervention: Intravenous adenosine 140 micrograms/kg/min for six minutes
Number of subjects: 15

Group type: COMPARATOR
Intervention: Oral dipyridamole suspension 300 mg
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Intravenous adenosine
Number of subjects: 15

Group type: COMPARATOR
Intervention: Oral dipyridamole
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Intravenous adenosine and oral dipyridamole
Number of subjects: 15
Study: 6693039

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 18

Group type: COMPARATOR
Intervention: Metoprolol
Number of subjects: 18
Study: 31407953

Group type: EXPERIMENTAL
Intervention: Father-daughter communication
Number of subjects: 193

Group type: COMPARATOR
Intervention: Communication style
Number of subjects: 193
Study: 29649227

Group type: EXPERIMENTAL
Intervention: Cleaner burning biomass-fuelled cookstoves
Number of subjects: 6168

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 6168
Study: 27955682

Group type: EXPERIMENTAL
Intervention: Telehealthcare (Telekit) solution
Number of subjects: 600

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 600
Study: 25217762

Group type: EXPERIMENTAL
Intervention: Verbal fluency task that elicited analytic thinking (Study 2)
Number of subjects: 990

Group type: EXPERIMENTAL
Intervention: Cognitive disfluency method to elicit analytic thinking (Study 3)
Number of subjects: 990

Group type: EXPERIMENTAL
Intervention: Cognitive disfluency method to elicit analytic thinking (Study 4)
Number of subjects: 990
Study: 21805226

Group type: EXPERIMENTAL
Intervention: CPAP + exercise
Number of subjects: 32

Group type: COMPARATOR
Intervention: CPAP
Number of subjects: 32
Study: 20551752

Group type: EXPERIMENTAL
Intervention: Triple target regimen (amplitude-modulated medium-frequency stimulation + EMG-biofeedback)
Number of subjects: 158

Group type: COMPARATOR
Intervention: EMG-biofeedback alone
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Triple target regimen
Number of subjects: 158
Study: 17534955

Group type: EXPERIMENTAL
Intervention: Pramipexole
Number of subjects: 0

Group type: COMPARATOR
Intervention: Levodopa
Number of subjects: 0
Study: 15611784

Group type: EXPERIMENTAL
Intervention: Capsaicin capsules (0.9 g red pepper; 0.25% capsaicin; 80,000 Scoville Thermal Units)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Capsaicin in tomato juice (0.9 g red pepper; 0.25% capsaicin; 80,000 Scoville Thermal Units)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo (offered in tomato juice or capsules)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Capsaicin conditions (both oral and gastrointestinal)
Number of subjects: 24
Study: 12198030

Group type: EXPERIMENTAL
Intervention: Ketamine 0.25 mg/kg
Number of subjects: 35

Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 35
Study: 10417874

Group type: EXPERIMENTAL
Intervention: Ajoene (0.6%, gel)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Terbinafine (1%, cream)
Number of subjects: 60
Study: 8524604

Group type: EXPERIMENTAL
Intervention: Electrical stimulation of the tibialis anterior muscle for 4 weeks at twice the motor threshold
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Electrical stimulation of the tibialis anterior muscle
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Electrical stimulation for 4 weeks at twice motor threshold
Number of subjects: 7
Study: 2196942

Group type: EXPERIMENTAL
Intervention: High S-phase fraction tumors
Number of subjects: 430

Group type: EXPERIMENTAL
Intervention: DNA aneuploidy
Number of subjects: 430

Group type: EXPERIMENTAL
Intervention: Positive nodes, large tumor size, DNA aneuploidy, high S-phase fraction, high grade of malignancy, lack of tubule formation, high mitotic index, pleomorphism, multifocal cancer, vascular invasion
Number of subjects: 430

Group type: EXPERIMENTAL
Intervention: Elastosis and presence of estrogen and progesterone receptors
Number of subjects: 430

Group type: EXPERIMENTAL
Intervention: Lymph node status, tumor size, S-phase fraction, multifocal growth pattern
Number of subjects: 430
Study: 6270950

Group type: EXPERIMENTAL
Intervention: Naloxone (2.5 microgram/kg i.v.)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 31502873

Group type: EXPERIMENTAL
Intervention: Performance-based social skills interventions (SSIs)
Number of subjects: 0
Study: 28401851

Group type: EXPERIMENTAL
Intervention: Regular home-visiting during pregnancy and the first year of life
Number of subjects: 117

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 117
Study: 25948515

Group type: EXPERIMENTAL
Intervention: Focused extracorporeal shock wave therapy (0.25 mJ/mm(2)) with three sessions of 2000 impulses in weekly intervals
Number of subjects: 250

Group type: COMPARATOR
Intervention: Placebo intervention
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Focused extracorporeal shock wave therapy (0.25 mJ/mm(2))
Number of subjects: 250
Study: 23624419

Group type: EXPERIMENTAL
Intervention: Vildagliptin 50mg twice a day in addition to metformin
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: Vildagliptin+metformin
Number of subjects: 171

Group type: COMPARATOR
Intervention: Placebo+metformin
Number of subjects: 171
Study: 21784309

Group type: EXPERIMENTAL
Intervention: Calcium tablet (600 mg once daily as CaCO3)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo tablet once daily
Number of subjects: 40
Study: 18795291

Group type: EXPERIMENTAL
Intervention: Erlotinib 50 mg daily with standard-dose cetuximab
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Bevacizumab 10 mg/kg biweekly
Number of subjects: 40
Study: 16915874

Group type: EXPERIMENTAL
Intervention: Work-related stress management program for 12 weeks
Number of subjects: 29

Group type: COMPARATOR
Intervention: No treatment for 12 weeks
Number of subjects: 29
Study: 15553594

Group type: EXPERIMENTAL
Intervention: n‐3 PUFA 6.6 g
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: n‐3 PUFA 2.0 g
Number of subjects: 60

Group type: COMPARATOR
Intervention: Olive oil
Number of subjects: 60
Study: 11033400

Group type: EXPERIMENTAL
Intervention: Foldable silicone intraocular lens (Allergan SI‐30) through a 3.2 mm incision
Number of subjects: 30

Group type: COMPARATOR
Intervention: Poly(methyl methacrylate) (PMMA) intraocular lens through a 5.0 mm incision
Number of subjects: 30
Study: 9062368

Group type: EXPERIMENTAL
Intervention: oral acyclovir 400 mg PO twice a day
Number of subjects: 27

Group type: COMPARATOR
Intervention: viral isolation
Number of subjects: 27
Study: 8444263

Group type: EXPERIMENTAL
Intervention: Auditory reaction time task while maintaining upright posture on a force platform; conditions of vision/surface not specified.
Number of subjects: 0
Study: 3756583

Group type: EXPERIMENTAL
Intervention: Ergonovine
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Cold pressor test
Number of subjects: 34
Study: 30852173

Group type: EXPERIMENTAL
Intervention: Text message reminders
Number of subjects: 187

Group type: COMPARATOR
Intervention: No text message reminders (Control)
Number of subjects: 187
Study: 29071464

Group type: EXPERIMENTAL
Intervention: Overnight fasting
Number of subjects: 0

Group type: COMPARATOR
Intervention: Glucagon infusion (elevated blood glucose levels)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low blood glucose after fasting
Number of subjects: 0
Study: 27423168

Group type: EXPERIMENTAL
Intervention: Light intensity exercise (rating of perceived exertion 11)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Moderate intensity exercise (rating of perceived exertion 13)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Hard intensity exercise (rating of perceived exertion 15)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Quiet rest (control group)
Number of subjects: 24
Study: 24815594

Group type: EXPERIMENTAL
Intervention: Training and experimental neck pain
Number of subjects: 3

Group type: COMPARATOR
Intervention: Training and no pain
Number of subjects: 3

Group type: COMPARATOR
Intervention: Pain and no training
Number of subjects: 3
Study: 22863265

Group type: EXPERIMENTAL
Intervention: Fluvastatin combined with PEG‐IFN/ribavirin
Number of subjects: 101

Group type: COMPARATOR
Intervention: PEG‐IFN/ribavirin without fluvastatin
Number of subjects: 101
Study: 20671564

Group type: EXPERIMENTAL
Intervention: HEART intervention (8 structured nurse education visits and telemonitoring)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Usual care and telemonitoring (control)
Number of subjects: 24
Study: 17938811

Group type: EXPERIMENTAL
Intervention: Lower tertile platelet count (<198 x 10(9)/L)
Number of subjects: 5256

Group type: EXPERIMENTAL
Intervention: Middle tertile platelet count (198-244 x 10(9)/L)
Number of subjects: 5256

Group type: EXPERIMENTAL
Intervention: Upper tertile platelet count (>244 x 10(9)/L)
Number of subjects: 5256

Group type: EXPERIMENTAL
Intervention: Platelet count
Number of subjects: 5256
Study: 16304303

Group type: EXPERIMENTAL
Intervention: Deep-breathing exercises
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (no breathing exercises)
Number of subjects: 90
Study: 11911935

Group type: EXPERIMENTAL
Intervention: 50 g amino-acid drink without tryptophan (depletion condition)
Number of subjects: 18

Group type: COMPARATOR
Intervention: 50 g amino-acid drink with tryptophan (placebo condition)
Number of subjects: 18
Study: 9717598

Group type: EXPERIMENTAL
Intervention: Nicardipine (30 micrograms.kg‐1)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Diltiazem (0.2 mg.kg‐1)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 60
Study: 7900508

Group type: EXPERIMENTAL
Intervention: IVF
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control (non-IVF infertility patients with singleton pregnancies and women with normal fertility with twin or triplet pregnancies)
Number of subjects: 90
Study: 2748310

Group type: EXPERIMENTAL
Intervention: Catch trial (CT) group
Number of subjects: 48

Group type: COMPARATOR
Intervention: No catch trial (no-CT) group
Number of subjects: 48
Study: 334028

Group type: EXPERIMENTAL
Intervention: Oestriol succinate therapy (2 mg/day)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Oestriol succinate therapy
Number of subjects: 27
Study: 31468735

Group type: EXPERIMENTAL
Intervention: Adaptive Cue condition (Cue)
Number of subjects: 35

Group type: COMPARATOR
Intervention: No-Cue condition (No-Cue)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Typically Developing Controls (TD)
Number of subjects: 35
Study: 31272988

Group type: EXPERIMENTAL
Intervention: VRC07-523LS
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: PGT121
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study: 28408545

Group type: EXPERIMENTAL
Intervention: Multifaceted service involving a pharmacist integrated into a medical centre to assist patients after hospitalisation; includes follow-up and medication reconciliation.
Number of subjects: 2240

Group type: COMPARATOR
Intervention: Usual care (control group) where patients self-organise a visit to their GP after hospital discharge.
Number of subjects: 2240

Group type: EXPERIMENTAL
Intervention: Cost analysis comparing healthcare costs associated with the intervention to those of usual care.
Number of subjects: 2240
Study: 26261095

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral intervention
Number of subjects: 146

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 146
Study: 23886520

Group type: EXPERIMENTAL
Intervention: High n-3 plus low n-6 (H3-L6) intervention
Number of subjects: 67
Study: 22080459

Group type: EXPERIMENTAL
Intervention: e-learning intervention (1-2 hours duration)
Number of subjects: 162

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 162